FOGSI Consensus Redefines Endometriosis Care with Oral GnRH Antagonist, Elagolix Medical Dialogues
Endometriosis is a benign gynecological condition characterized by the presence of functional endometrial tissue outside the uterine cavity. Although it most commonly affects pelvic organs, bowel involvement is uncommon, and …
Endometriosis is a frequent chronic estrogen-dependent condition that can significantly impair fertility and reduce the quality of life in affected individuals. Women with endometriosis face a 30-50% risk of infertility. …
Gonadotropin-releasing hormone (GnRH) antagonists inhibit estrogen synthesis and secretion, making them promising treatment options for estrogen-dependent diseases, such as endometriosis. This study developed a population pharmacokinetic/pharmacodynamic (PK/PD) model for merigolix, …
United States GnRH Agonists and Antagonists Drugs openPR.com
Endometriosis is a chronic inflammatory condition affecting ~10% of reproductive-age individuals and contributing significantly to infertility, pain, and reduced quality of life. Since our 2020 review, new pharmacologic strategies, updated …
This systematic review and meta-analysis compared the efficacy of dienogest (DNG) and gonadotropin-releasing hormone (GnRH) agonists in the management of endometriosis-related symptoms following surgical intervention, their related adverse effects, and …
Relugolix, an oral GnRH receptor antagonist, is effective in treating uterine myomas and endometriosis. However, concerns persist regarding the venous thromboembolism (VTE) risk associated with its combination with oral estradiol …
This study aimed to identify risk and protective factors for postoperative recurrence of deep infiltrating endometriosis (DIE). We analyzed 320 patients undergoing laparoscopic excision with ≥ 6 years follow-up at …